The Real-life Safety and Efficacy of Vardenafil: An International Post-marketing Surveillance Study - Results from 29 358 German Patients
| Autor: | K. Stauch, H. Landen, J. Zumbé, H. Van Ahlen |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Surveillance study Dose Phosphodiesterase Inhibitors International Cooperation Postmarketing surveillance 030204 cardiovascular system & hematology Biochemistry Piperazines 03 medical and health sciences 0302 clinical medicine Erectile Dysfunction Vardenafil Dihydrochloride Germany Surveys and Questionnaires Internal medicine Humans Medicine In patient Prospective Studies Sulfones Prospective cohort study Aged Triazines business.industry Penile Erection Biochemistry (medical) Imidazoles Cell Biology General Medicine Middle Aged medicine.disease Surgery Treatment Outcome Erectile dysfunction Vardenafil 030220 oncology & carcinogenesis Observational study Safety business medicine.drug |
| Zdroj: | Journal of International Medical Research. 33:337-348 |
| ISSN: | 1473-2300 0300-0605 |
| Popis: | We assessed the safety, efficacy and patient acceptability of vardenafil (Levitra®, Bayer HealthCare, Leverkusen, Germany) under real-life conditions in patients with erectile dysfunction (ED) in a multinational post-marketing surveillance study. An initial and up to two follow-up visits were documented for 29358 German ED patients receiving vardenafil. Patients were interviewed about overall treatment success, and individual sexual attempts were evaluated in a patient questionnaire. Overall erectile improvement was reported by 93.9% of physicians, and similar improvement rates were reported for both 10 mg and 20 mg vardenafil dosages. Most patients experienced improved erections after the first (73.6%) or second (88.5%) tablet. Sexual attempts were successful with respect to partner penetration in 94.9% of patients and with respect to maintenance of erection during intercourse in 87.7% of patients. Adverse drug reactions were very rare (1.3% of patients). Vardenafil was highly effective, reliable and well tolerated in ED patients treated under real-life conditions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|